BGLAP and type 1 diabetes mellitus: Conversely, similar skeletal alterations as in Ocn−/− mice characterized by enhanced bone mass accrual were noted, suggesting that bone-intrinsic OCN biology might be conserved more strongly between the two species.66 Pharmacologically, treatment of SREBP1c transgenic rats with recombinant OCN had no apparent effect on glucose metabolism.132 On the other hand, recombinant OCN enhanced insulin secretion and glycemic control in a rat model of streptozotocin-induced type I diabetes, while the same parameters remained unaltered under homeostatic conditions.133